”Real World CFTR Modulation: Opportunities, consequences and challenges”
We are pleased to welcome healthcare professionals working in the field of Cystic Fibrosis to participate in our Chiesi CF Academy webinar with the title “Real World CFTR Modulation: Opportunities, consequences and challenges”, with the aim of sharing best practice and experience to all CF-centres in the Nordics.
In this session Professor Barry Plant will examine current clinical trial and real-world data exploring outcomes post modulation in CF with a focus on ETI. He will discuss the many pulmonary and extra pulmonary opportunities and in addition consequences (both positive and negative). He will also explore the data available around long-term function improvement post CFTR modulation, how long does it last for and the role on inhaled antibiotics in this new era of CF care.
Speaker: Professor Barry Plant from Cork University Hospital
Professor Barry Plant MD, FRCPI, MFSEM is a Consultant Respiratory Physician, Clinical Director for Medicine and the Director of the Adult CF Centre at Cork University Hospital (CUH)-University College Cork, an executive member of the CF Registry of Ireland, and a former executive board member of ECFS.
Agenda
12.00-12.05
Welcome and introduction, Laila Massamiri, Nordic Medical Advisor, Chiesi Pharma and Pernilla Svahn, Marketing Manager Norway
12.05-12.45
Real World CFTR Modulation: Opportunities, consequences and challenges, Prof. Plant
12.45-13.00
Summarize and Q&A, Prof. Plant
We are looking forward to seeing you at the meeting!
Warm welcome!
Laila Massamiri
Nordic Medial Advisor
[email protected]
+46 706 813 342
Pernilla Svahn
Marketing Manager Norway
[email protected]
+46 708 582 128
If you have any questions, contact Laila Massamiri, Nordic Medical Advisor, Chiesi.
Email: [email protected] | Tel: + 46 706 813 342
For technical issues, contact TTV. Email: [email protected] | Tel: +46 732 001 947
This meeting is arranged by Chiesi Pharma AB. Chiesi is responsible for the costs of the lecturer and all costs associated with the implementation of the meeting. The transfer of values should not unduly affect the health care provider to a decision to recommend, prescribe, buy, give, sell or manage any of the client’s products.